PR Newswire
LAS VEGAS, Feb. 5, 2026
According to DelveInsight’s analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025-2034), driven by the launch of emerging therapies such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others, and healthcare spending in the 7MM.
LAS VEGAS, Feb. 5, 2026 /PRNewswire/ — DelveInsight’s Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary sclerosing cholangitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Primary Sclerosing Cholangitis Market Summary
- The total primary sclerosing cholangitis treatment market size is expected to grow positively by 2034 in the leading markets.
- The United States accounts for the largest market size of primary sclerosing cholangitis, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
- In 2024, the total diagnosed prevalent cases in the 7MM were found to be 90K.
- Leading primary sclerosing cholangitis companies, such as LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, and others, are developing new primary sclerosing cholangitis treatment drugs that can be available in the primary sclerosing cholangitis market in the coming years.
- The promising primary sclerosing cholangitis therapies in clinical trials include LB-P8, Volixibat, IQIRVO (Elafibranor), Nebokitug, and others.
Discover how large is the PSC market now and what will it be in 2034 @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Primary Sclerosing Cholangitis Market
- Rising PSC Prevalence: PSC incidence is increasing alongside related conditions like inflammatory bowel disease, liver failure, and bile duct cancer. This boosts demand for diagnostics and therapies, with prevalence estimates as high as 16.2 per 100,000 in high-incidence regions.
- Enhanced Diagnostic Capabilities: Advancements in non-invasive imaging and biomarker technologies (e.g., MRCP, ERCP, cholangiography, and emerging serological tests) are improving early detection.
- Emerging PSC Therapeutic Candidates in Development: Promising candidates such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others reflect growing efforts to target both the molecular and symptomatic aspects of the disease.
Primary Sclerosing Cholangitis Market Analysis
- The management of primary sclerosing cholangitis remains challenging due to the absence of an established curative therapy.
- Ursodeoxycholic acid (UDCA) has been widely studied as a potential treatment; however, clinical guidelines provide conflicting recommendations regarding its use.
- Multiple pharmacologic therapies, including prednisolone, budesonide, colchicine, penicillamine, azathioprine, tacrolimus, methotrexate, mycophenolate mofetil, and anti-tumor necrosis factor agents, have been evaluated without demonstrating proven clinical benefit in PSC.
- For patients with dominant biliary strictures, defined as narrowing of less than 1.5 mm in the common bile duct or less than 1.0 mm in the hepatic ducts, who present with pruritus or cholangitis, endoscopic retrograde cholangiopancreatography (ERCP) with balloon dilation is recommended to relieve symptoms.
- Surgical management options for PSC include biliary reconstructive procedures such as choledochoduodenostomy and choledochojejunostomy to improve bile drainage.
- The PSC market remains largely untapped due to the lack of approved disease-modifying therapies.
- Current treatment strategies are primarily symptomatic and have limited impact on disease progression, underscoring a substantial unmet medical need.
- Pharmaceutical development in PSC has been constrained by the disease’s rarity, complex pathophysiology, and lack of validated biomarkers for clinical and regulatory advancement.
- Despite these challenges, the increasing prevalence of disease, orphan drug incentives, and high unmet demand create significant opportunities for innovation.
- Overall, PSC represents a low-competition, high-value niche where targeted investment and novel therapeutics could transform patient outcomes and unlock a largely unexplored market.
Primary Sclerosing Cholangitis Competitive Landscape
Some of the PSC therapies in the pipeline include LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others.
LISCure Biosciences’ LB-P8 is an orally administered, once-daily live biotherapeutic consisting of a single microbial strain designed to modulate fibrosis and inflammation via the gut-liver axis. Its anti-fibrotic and anti-inflammatory activity has been demonstrated across multiple preclinical models, including primary sclerosing cholangitis (PSC), metabolic dysfunction-associated steatohepatitis (MASH), and inflammatory bowel disease (IBD).
Mirum Pharmaceuticals’ Volixibat is an oral, minimally absorbed inhibitor of the ileal bile acid transporter (IBAT) that reduces bile acid levels by preventing their intestinal reabsorption, thereby lowering systemic and hepatic bile acid exposure. The compound is currently being evaluated in the Phase IIb VISTAS trial for PSC. In 2024, the study met its prespecified efficacy and safety criteria at a blinded interim analysis for dose selection, highlighting its encouraging clinical potential. No new safety signals were observed, with diarrhea as the most common mild-to-moderate adverse event.
Ipsen’s Elafibranor is an oral agonist of peroxisome proliferator-activated receptors (PPAR) α and δ. Activation of these receptors reduces bile acid toxicity and improves cholestasis by regulating bile acid synthesis, detoxification, and transporter expression. In addition, activation of PPARα and PPARδ confers anti-inflammatory effects through multiple signaling pathways.
The anticipated launch of these emerging therapies are poised to transform the primary sclerosing cholangitis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the primary sclerosing cholangitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which emerging drugs will affect the PSC market @ Primary Sclerosing Cholangitis Drugs Market
Recent Developments in the Primary Sclerosing Cholangitis Market
- In December 2025, Chemomab Therapeutics Ltd. reported that findings from its Phase 2 SPRING study evaluating nebokitug in patients with primary sclerosing cholangitis (PSC) have been published in the latest issue of the American Journal of Gastroenterology.
- In September 2025, Mirum Pharmaceuticals completed enrollment in the Phase IIb VISTAS trial evaluating volixibat, an oral IBAT inhibitor, for cholestatic pruritus in PSC. The study met its pre-specified efficacy and safety thresholds at the 2024 interim analysis, with topline results expected in Q2 2026.
- In April 2025, late-breaking data demonstrated that elafibranor demonstrated dose-dependent efficacy and a favorable safety profile over 12 weeks in patients with PSC, a rare liver disease with no approved treatments.
What is Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease characterized by ongoing inflammation, fibrosis, and progressive narrowing of the bile ducts inside and outside the liver. This leads to impaired bile flow (cholestasis), causing bile to accumulate in the liver and gradually resulting in liver damage, cirrhosis, and eventually liver failure in some patients. PSC is strongly associated with inflammatory bowel disease, particularly ulcerative colitis, and often affects younger to middle-aged adults. The disease course is variable and unpredictable, with patients at increased risk of complications such as recurrent cholangitis, cholangiocarcinoma, and colorectal cancer. Currently, there is no curative medical therapy for PSC, and liver transplantation remains the only definitive treatment for advanced disease.
Primary Sclerosing Cholangitis Epidemiology Segmentation
The primary sclerosing cholangitis epidemiology section provides insights into the historical and current primary sclerosing cholangitis patient pool and forecasted trends for the leading markets. PSC affects men about twice as often as women. Although it can occur at any age, it most commonly develops in middle-aged adults.
The primary sclerosing cholangitis treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Prevalent Cases of PSC
- Total Diagnosed Prevalent Cases of PSC
- Gender-specific Cases of PSC
- Comorbidity-specific Cases of PSC
- Treated Cases of PSC
Primary Sclerosing Cholangitis Market Forecast Report Metrics
Details
Study Period
2020-2034
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain),
the United Kingdom, and Japan].
Primary Sclerosing Cholangitis Epidemiology Segmentation Total Prevalent Cases of PSC, Total Diagnosed Prevalent Cases of PSC,
Gender-specific Cases of PSC, Comorbidity-specific Cases of PSC, and
Treated Cases of PSC
Key Primary Sclerosing Cholangitis Companies LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab
Therapeutics, and others
Key Primary Sclerosing Cholangitis Therapies
LB-P8, Volixibat, IQIRVO (Elafibranor), Nebokitug, and others
Scope of the
Primary Sclerosing Cholangitis
Market Report
- Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and emerging therapies
- Primary Sclerosing Cholangitis Market Dynamics: Key Market Forecast Assumptions of Emerging Primary Sclerosing Cholangitis Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Primary Sclerosing Cholangitis Market Access and Reimbursement
Download the report to understand what factors are driving the PSC therapeutic market @ Primary Sclerosing Cholangitis Market Forecast
Table of Contents
1 Primary Sclerosing Cholangitis Market Key Insights
2 Primary Sclerosing Cholangitis Market Report
Introduction
3
PSC Market Overview at a Glance
3.1 Market Share (%) Distribution of PSC by Therapies in
2020
3.2 Market Share (%) Distribution of PSC by Therapies in
2034
4 Epidemiology and Market Forecast Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Clinical Manifestations
7.3
Causes and Risk Factors
7.4
Pathophysiology
7.5
Diagnosis
7.6 Primary Sclerosing Cholangitis Treatment and
Management
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3 Total Diagnosed Prevalent Cases of PSC in the 7MM
8.4
The United States
8.4.1
Total Prevalent Cases of PSC
8.4.2
Total Diagnosed Prevalent Cases of PSC
8.4.3
Gender-specific Cases of PSC
8.4.4
Comorbidity-specific Cases of PSC
8.4.5
Treated Cases of PSC
8.5
EU4 and the UK
8.6
Japan
9 Primary Sclerosing Cholangitis Patient Journey
10 Emerging Primary Sclerosing Cholangitis Drugs
10.1
Key Cross Competition
10.2
LB-P8: LISCure Biosciences
10.2.1
Product Description
10.2.2
Other Development Activities
10.2.3
Clinical Trial Information
10.2.4
Safety and Efficacy
10.2.5
Analyst Views
10.3
Volixibat: Mirum Pharmaceuticals
10.4
IQIRVO (Elafibranor): Ipsen
To be Continued in Report….
11
PSC Market: Major Market Analysis
11.1
Key Findings
11.2 Key Primary Sclerosing Cholangitis Market Forecast
Assumptions
11.3 Primary Sclerosing Cholangitis Market Outlook
11.4
Attribute Analysis
11.5
Total Market Size of PSC in the 7MM
11.6 Total Market Size of PSC by Therapies in the 7MM
11.7 The United States Primary Sclerosing Cholangitis
Market Size
11.7.1
Total Market Size of PSC in the US
11.7.2
Market Size of PSC by Therapies in the US
11.8 EU4 and the UK Primary Sclerosing Cholangitis Market
Size
11.9 Japan Primary Sclerosing Cholangitis Market Size
12
KOL Opinion Leaders’ Views on PSC
13 Primary Sclerosing Cholangitis Market SWOT Analysis
14 Primary Sclerosing Cholangitis Market Unmet Needs
15 Primary Sclerosing Cholangitis Market Access and
Reimbursement
16
Acronym and Abbreviations
17
Bibliography
18 Primary Sclerosing Cholangitis Market Report
Methodology
Related Reports
Primary Sclerosing Cholangitis Clinical Trial Analysis
Primary Sclerosing Cholangitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Primary Sclerosing Cholangitis companies, including Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic, and others.
Inflammatory Bowel Disease Market
Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IBD companies including Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.
Ulcerative Colitis Market
Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others.
Crohn’s Disease Market
Crohn’s Disease Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn’s disease companies including RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur [email protected]+14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/primary-sclerosing-cholangitis-market-outlook-highlights-rising-demand-and-expanding-treatment-landscape-throughout-the-forecast-period-20252034–delveinsight-302679746.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…